
Shujie Gao,1 Yiqing Zhao,2 Huihong Ji,3 Qingfang Lu,3 Yuqi Zhang,1 Mengru Liu,1 Junping Wang3 1Department of Gastroenterology, Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, Shanxi, People’s Republic of China; 2Department of Gastroenterology, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, People’s Republic of China; 3Endoscopy Center, Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, Shanxi, People’s Republic of ChinaCorrespondence: Junping Wang, Endoscopy Center, Shanxi Provincial Hospital of Traditional Chinese Medicine, Qingnian Road, Yingze District, Taiyuan, Shanxi, People’s Republic of China, Email wangjp8396@sxmu.edu.cnAbstract: Gastric cancer remains a major global health burden, and chronic atrophic gastritis (CAG) and gastric intestinal metaplasia (GIM) are important premalignant conditions. The risk of progression, however, varies considerably between individuals, making reliable risk stratification central to decisions on surveillance. Histological staging remains the most established approach. In a recent meta–analysis of prospective cohorts, Operative Link on Gastritis Assessment (OLGA) stages III–IV and OLGIM (Operative Link on Gastric Intestinal Metaplasia Assessment) stages III–IV were associated with substantially higher risks of gastric cancer than stages 0–II, with risk ratios of 32.31 and 12.38, respectively. Endoscopic assessment adds information on the distribution of mucosal abnormalities and can improve biopsy targeting; an EGGIM score > 4 has shown 95.7% sensitivity and 91.4% specificity for identifying OLGIM stages III–IV. Helicobacter pylori eradication reduces subsequent gastric cancer risk, but surveillance remains necessary in patients with advanced atrophy, extensive GIM, or previous gastric neoplasia. Serological biomarkers may help identify individuals who should undergo endoscopy, although variation in assay thresholds and population characteristics limits their use for definitive risk staging. Artificial intelligence is also being explored to improve diagnostic consistency. In a multicentre pathology study, a deep–learning model achieved external–test AUCs of 0.884 for intestinal metaplasia and 0.877 for atrophy. Current evidence therefore favours combining these approaches according to their clinical roles rather than treating them as interchangeable tools: histology remains the basis of risk staging, endoscopy refines mucosal assessment and biopsy, biomarkers are most useful for triage, and artificial intelligence may support interpretation. Whether such integrated strategies improve surveillance efficiency or clinical outcomes still requires prospective, externally validated studies.Keywords: chronic atrophic gastritis, gastric intestinal metaplasia, gastric cancer, OLGA, OLGIM, artificial intelligence
Miguel A Arce-Huamani,1 Irene Cárdenas-Vela,2 Jacqueline Abad-Núñez,2 Luis Cervera-Caballero,2 Ofelia Castillo-Contreras,2 Ariana Alcarraz-Castillo,1 Ernesto David Herrera-Castillo,1 Maria D Vallejo-Jaime11Research for Evidence, Care, and Public Health, Programa Académico de Medicina Humana, Facultad de Ciencias de la Salud, Universidad Privada Norbert Wiener, Lima, Peru; 2Gastroenterology Service, Hospital Nacional Edgardo Rebagliati Martins, Lima, PeruCorrespondence: Miguel A Arce-Huamani, Research for Evidence, Care, and Public Health, Programa Académico de Medicina Humana, Facultad de Ciencias de la Salud, Universidad Privada Norbert Wiener, Avenida Salaverry 1230, Lima, Peru, Tel +51 926 896 694, Email miguelangel.arce@uwiener.edu.peIntroduction/Objective: Diagnostic delay in Crohn’s disease has been associated with adverse outcomes, including intestinal surgery. Evidence from Latin American tertiary referral settings is limited. We evaluated the association between diagnostic delay and Crohn’s disease–related intestinal surgery in a Peruvian national referral hospital.Methods: This retrospective observational analytical study included adults with confirmed Crohn’s disease followed at Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, between April 2020 and February 2025. Patients with complete clinical information, including documented diagnostic-delay categories and intestinal surgery status, were included. Diagnostic delay was categorized as > 12 versus ≤ 12 months. Logistic regression estimated crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs).Results: The cohort included 47 patients; mean age was 50.0 ± 20.7 years, 55.3% were male, and 53.2% had undergone intestinal surgery. Overall, 29.8% had diagnostic delay > 12 months; this was documented in 44.0% of patients with surgery versus 13.6% without surgery. Diagnostic delay > 12 months was associated with higher odds of surgery in crude analysis (OR 4.98; 95% CI 1.17– 21.24; p=0.030). After adjustment, the association remained positive but imprecise (aOR 3.97; 95% CI 0.87– 18.15; p=0.075).Conclusion: Diagnostic delay > 12 months was more frequent among patients with Crohn’s disease–related intestinal surgery, while the adjusted estimate remained positive but imprecise. These findings highlight the potential clinical relevance of diagnostic delay and warrant confirmation in larger prospective studies.Keywords: Crohn’s disease, diagnostic delay, intestinal surgery, tertiary hospital
Ahmed SalmanInternal Medicine Department, Faculty of Medicine, Cairo University, Cairo, EgyptCorrespondence: Ahmed Salman, Internal Medicine Department, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt, Tel +20 100 046 8664, Email awea84@kasralainy.edu.egAbstract: Eosinophilic gastritis (EoG) and eosinophilic duodenitis (EoD) are chronic, immune-mediated gastrointestinal disorders in which tissue eosinophil density is both an accessible biomarker and a common trial endpoint. Recent targeted studies have shown trial-level divergence between objective endpoints and patient-reported outcomes. This narrative review examines mechanisms, measurement tools, conventional treatment, and biologic studies published or registered through October 2026. In a 26-patient benralizumab trial, histologic remission occurred in 77% of treated patients and 8% of placebo recipients, yet symptom and endoscopic changes were not statistically different. In the DEGAS trial, dupilumab improved histology and endoscopy at 12 weeks, while the symptom change did not differ significantly from placebo. Two Phase 3 lirentelimab trials with registry-posted results met histologic endpoints without significant symptom benefit. Paired individual data are needed to establish within-person discordance. These findings do not make eosinophils unimportant. They show that target engagement, biological disease control, patient status, treatment success, and durability answer different questions. We propose a provisional framework that separates biological disease activity, structural damage, and patient status; treats burden and safety as modifiers of treatment success; and applies duration as a temporal qualifier. The framework favors domain-specific reporting and named discordance states over a single remission score. Patchy disease, variable microscopic field geometry, shallow mucosal sampling, nonspecific symptoms, and limited EoD-specific validation remain important constraints. Patient-informed international consensus and prospective longitudinal testing are needed before the proposed states can guide routine care.Keywords: eosinophilic gastritis, eosinophilic duodenitis, biologic therapy, treatment outcome, remission induction
Bianca Loyo Pona Schiavetti,1 Rodrigo Galhardi Gasparini21IBD Outpatient Clinic, Prefeitura Municipal de Santos, Santos, São Paulo, Brazil; 2Digestive Surgery and Gastroenterology Department, Sete Specialized Medical Center, Marília, São Paulo, BrazilCorrespondence: Rodrigo Galhardi Gasparini, Digestive Surgery and Gastroenterology Department, Sete Specialized Medical Center, Av. Sete de Setembro 979, Marília, São Paulo, 17.502-020, Brazil, Tel +55 14 3113-9119, Email rodrigoggasparini@gmail.comIntroduction: Subcutaneous infliximab (SC-IFX) has emerged as an alternative maintenance therapy for inflammatory bowel disease (IBD), offering absorption and sustained systemic exposure. Although higher and more stable serum concentrations have been reported with SC-IFX, prospective real-world data evaluating pharmacokinetic evolution after transition from intravenous infliximab (IV–IFX) remain limited, particularly in Latin America. We assessed infliximab trough concentrations following transition from IV–IFX to SC-IFX and explored associations with biomarkers and clinical outcomes.Methods: ISLASIS was a prospective, open-label study including adults with Crohn’s disease (CD) or ulcerative colitis (UC) receiving IV–IFX. All transitioned to SC-IFX and were evaluated at baseline (V1), week 12 (V2), and week 24 (V3). Infliximab trough concentrations were measured at each visit. Fecal calprotectin and clinical indices were assessed at baseline and week 24. Subgroup analyses explored pharmacokinetic behavior according to disease phenotype, prior biologic exposure, and IV regimen.Results: Nineteen patients were included; 89.5% had CD, with 35.3% presenting perianal disease. Median trough concentrations increased from 8.7 μg/mL at baseline to 20.0 μg/mL at week 12 and remained at 20.0 μg/mL at week 24 (p=0.00029). Fecal calprotectin decreased from 239 to 142 μg/g (p=0.00097). Median Harvey–Bradshaw Index decreased from 8 to 3, while partial Mayo score declined from 2 to 0. Increases in serum infliximab concentrations were observed across the clinical and treatment subgroups evaluated, although interpretation of concentrations above 20 μg/mL was limited by the assay measurement range. No anti-infliximab antibodies were detected. One mild, self-limited injection-site reaction occurred.Conclusion: Transition from IV–IFX to SC-IFX was associated with rapid and sustained increases in trough concentrations, reductions in fecal calprotectin, and favorable changes in clinical activity scores. These findings should be interpreted in light of the small sample size and the upper measurement limit of the infliximab assay.Clinical Trial Registration: This investigator-initiated prospective observational study was not registered in a clinical trial registry because treatment allocation was not determined by the study protocol. All participants received standard-of-care treatment, and the decision to switch from intravenous to subcutaneous infliximab was made as part of routine clinical practice.Keywords: crohn´s disease, ulcerative colitis, subcutaneous, infliximab, trough level
Michael Colwill,1,2 Richard Pollok,1,2 Chandni Radia,1,3 Leighton J Seal,2,4 Andrew Poullis1,21Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, London, UK; 2Institute of Infection and Immunity, City St George’s, University of London, London, UK; 3Department of Gastroenterology, King’s College Hospital NHS Foundation Trust, London, UK; 4The Tavistock and Portman NHS Foundation Trust, London, UKCorrespondence: Michael Colwill, Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, Blackshaw Road, London, SW17 0QT, UK, Email Michael.colwill@nhs.netPurpose: Transgender and gender non-conforming (TGNC) individuals are under-represented in inflammatory bowel disease (IBD) research, and little is known about their diagnostic experiences, disease burden, mental health comorbidity, or quality of life (QoL). We therefore aimed to characterise clinical features, diagnostic timelines, comorbidity, and QoL among TGNC people with IBD and to contextualise key outcomes using a matched cisgender cohort.Patients and Methods: We conducted a nationwide cohort study within the IBD BioResource population. Using questionnaires and linked BioResource data, we collected information on demographics, clinical history, gender-affirming care, comorbidity, and QoL. TGNC participants were matched to cisgender controls by sex and age category for a contextual and exploratory comparison. Analyses were performed using regression models.Results: Thirty-nine TGNC participants responded (46.2% Crohn’s disease, 43.6% ulcerative colitis, 10.3% IBD-unclassified). Median time from symptom onset to diagnosis was 10.5 months (interquartile range 6.0– 18.0), 62.3% reported prior hospitalisation and 28.2% prior IBD surgery. Psychiatric comorbidity was frequent (79%). Gender-affirming hormone therapy was reported in 30.7% and prior gender-affirming surgery in 17.9%. Matched analyses demonstrated a trend towards longer diagnostic delays and higher rates of hospitalisation and IBD-related surgery in TGNC participants. Psychiatric comorbidity was significantly higher (79.5% vs 56.8%, p=0.033). QoL impairment was substantial and broadly comparable between groups.Conclusion: TGNC individuals with IBD demonstrated a high burden of psychiatric comorbidity and signals of longer diagnostic timelines and poorer disease control compared with cisgender peers. These findings highlight potential disparities across IBD care pathways and underscore the need for larger, dedicated studies.Keywords: ulcerative colitis, Crohn’s disease, inflammatory bowel disease, transgender persons, quality of life